A Complete Response Letter (CRL) is the FDA's way of saying not yet. It is the formal response sent when an application has been reviewed and the agency cannot approve it as submitted — but is willing to consider a resubmission once the listed issues are addressed.
Critically, a CRL is not a denial. The application stays open; the sponsor can resubmit. But the original PDUFA cycle is over, the stock moves immediately, and the resubmission timeline can be 2–18 months depending on how much new work is required.
What goes in a CRL
The letter lists every "deficiency" the FDA identified. Common categories:
- Clinical — the trial design didn't isolate efficacy, more data is needed
- CMC (Chemistry, Manufacturing, Controls) — facility inspection issues, batch consistency
- Labeling — language disputes about indication or warnings
- Statistical — primary endpoint analysis is questionable
- Safety — long-term follow-up data is insufficient
- REMS — risk evaluation strategy needs strengthening
CRLs are confidential between the FDA and the sponsor. The sponsor discloses them — usually a same-day 8-K filing with selected (often paraphrased) language.
The stock impact
CRLs are reliably brutal:
- Average single-day drop: 30–50% for SMID-cap biotechs with one major asset
- Mega-cap biotechs: 5–15% drops for sBLA CRLs on a single indication
- Recovery: rarely full — even when the resubmission succeeds, the time-value-of-money and dilution risk weigh
How to read CRL language
The 8-K paraphrase matters. Pay attention to:
- "Additional clinical data" → another trial may be needed (worst case)
- "CMC" or "manufacturing" only → usually faster fix, often 6 months
- "Labeling discussion" → minor, weeks-to-months to resolve
- "Type A meeting" or "Type B meeting" reference → sponsor is actively engaging FDA on next steps
A CRL that mentions only CMC issues is materially different from one that mentions clinical efficacy questions. The first might add 6 months; the second might invalidate the asset.
Recent examples
- 2024 Q1 — Sarepta's Elevidys CRL on a manufacturing issue → relatively contained drop, expansion eventually approved
- 2024 Q3 — Multiple oncology CRLs from accelerated-approval confirmatory data → consistent pattern of FDA wanting overall-survival not just response-rate
What Yeji surfaces
Our catalyst feed flags CRLs the moment the company files an 8-K — usually within hours of the FDA letter. We tag the catalyst with confidence and link to the source filing so you can read the language yourself.